Biospecimen and Pathology Core

文摘：生物质学家与病理学核心 生物检验和病理核心的目的是提供生物检验和病理学服务 支持计划中的两个LI-CAD P20项目以及在 开发研究计划，并为P50孢子的扩展服务做准备。生物菌素 CORE提供组织化验解释方面的专业知识，特别是在生物标记物方面 研究、确保生物检疫的质量标准和合乎道德的使用，并在 LI-CAD研究者的组织学、数字组织学、免疫组织化学和显微解剖。 SA1.为AI/AN肝病患者的项目1和2提供所需的生物检疫药物， 肝硬变和肝细胞癌，以及来自适当的非AI/AN对照/对照患者 我们的LI-CAD项目将从以下来源获得血浆、血清、肝组织和肝细胞癌组织标本 支持LI-CADP20研究的生物库：1)一个真正非凡和独特的生物谱库 阿拉斯加土著(AN)慢性肝病患者的样本(“生物库”)来自阿拉斯加土著 部落健康联盟(ANTHC)；2)来自美国印第安人(AI)患者的生物谱库 Cherokee Nation Health Service(CNHS)(“人工智能生物仓库”)提供的慢性肝病；以及3)两个大的 非人工智能/AN，多种族/多民族生物库，将提供来自非AI/AN的比较样本 病人。 AN生物资源库包括从&gt；3500前瞻性和纵向收集的40,000个生物标本 ANTHC肝病和肝炎项目的患者(安克雷奇，AK)。这是由布莱恩博士执导的 McMahon，Li-CAD BioSpecimen Core的PI和P20 Li-CAD的co-PI，这将起到流线型的作用 LI-CAD研究人员获取这些生物标本的途径。来自这些生物储存库的生物样品将支持 项目1和2，以及未来的发展研究项目和扩大的P50项目 SA2.扩大美国印第安人肝病、肝硬变和糖尿病患者的生物谱库 总部设在切诺基国家医疗服务中心(CNHS，Tahlequah，俄克拉荷马州)，并仿照我们现有的， ANTHC的阿拉斯加原住民患者的大型生物库。 我们将增加我们的生物标本和从美国印第安人病人中招募病人的新的 与切诺基国家卫生服务机构(CNHS)合作。我们将利用阿拉斯加原住民的专业知识 生物库为CNHS的美国印第安人患者建立类似的肝病生物库。这 将是一个无价的资源，特别是当我们扩展到P50孢子的时候。 SA3.提供组织学、数字组织学、免疫组织化学和 LI-CAD研究人员的显微解剖

ABSTRACT: BIOSPECIMEN AND PATHOLOGY CORE The purpose of the Biospecimen and Pathology Core is to provide biospecimens and pathology services to support the two planned Li-CAD P20 Projects and those research studies proposed in the context of the Developmental Research Program and to prepare for a P50 SPORE expansion of services. The Biospecimen Core provides expertise in the interpretation of tissue-based assays especially in the context of biomarker studies, ensures quality standards and the ethical use of biospecimens and provides Core services in histology, digital histology, immunohistochemistry and microdissection for Li-CAD investigators. SA1. Provide biospecimens needed for Projects 1 and 2 from AI/AN patients with liver disease, cirrhosis and HCC, as well as from appropriate non-AI/AN comparison/control patients Our Li-CAD project will obtain plasma, serum, liver tissue and HCC tissue specimens from the following biorepositories that will support the Li-CAD P20 studies: 1) a truly remarkable and unique biospecimen bank of samples from Alaska Native (AN) patients with chronic liver disease (“AN biorepository”) from the Alaska Native Tribal Health Consortium (ANTHC); 2) a biospecimen bank of samples from American Indian (AI) patients with chronic liver disease from the Cherokee Nation Health Service (CNHS) (“AI biorepository”) ; and 3) two large non-AI/AN, multiracial/multiethnic biorepositories, that will provide comparison specimens from non-AI/AN patients. The AN biorepository includes >40,000 prospectively and longitudinally collected biospecimens from >3500 patients at the Liver Disease and Hepatitis Program of the ANTHC (Anchorage, AK). This is directed by Dr. Brian McMahon, the PI of the Li-CAD Biospecimen Core and co-PI of the P20 Li-CAD, which will serve to streamline access to these biospecimens for Li-CAD investigators. Biospecimens from these biorepositories will support Projects 1 and 2, as well as future developmental research projects and expanded P50 projects SA2. Expand the biospecimen repository of American Indian patients with liver disease, cirrhosis and HCC based at Cherokee Nation Health Service (CNHS, Tahlequah, OK) and pattern it after our existing, large biorepository of Alaska Native patients at ANTHC. We will augment our biospecimens and patient recruitment from American Indian patients by a new collaboration with Cherokee Nation Health Service (CNHS). We will use our expertise from Alaska Native biorepositories to establish analogous liver disease biorepositories for American Indian patients at CNHS. This will be an invaluable resource, especially as we expand to a P50 SPORE. SA3. Provide core pathology resources in histology, digital histology, immunohistochemistry and microdissection for Li-CAD investigators